Episode
Living with Spinal Muscular Atrophy: Genetic Testing, Therapy, and More
- Published
- Jan 30, 2026
- Duration seconds
- 2183
- Processing state
not_requested- Canonical source
- https://traffic.megaphone.fm/BMCL9677362564.mp3
Actions
POST https://stenobird.com/v1/public/podcasts/amplifying-the-patient-journey-6685265/episodes/living-with-spinal-muscular-atrophy-genetic-testing-therapy-and-more/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/amplifying-the-patient-journey-6685265/living-with-spinal-muscular-atrophy-genetic-testing-therapy-and-more.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Andrew Cherico, a student at the University of Central Florida, Orlando, FL, discusses his experience living with spinal muscular atrophy (SMA), the impacts of available treatments, and how the condition intersects with his passion for sports journalism. He is joined by John W. Day, MD, PhD, Professor of Neurology and Pediatrics, Director, Division of Neuromuscular Medicine at Stanford University School of Medicine, and Co-Director of Stanford’s Neuro IGNITE Center, Stanford, CA, who describes the importance of genetic testing, the landscape of available SMA treatments, and the significance of the newly approved one-time gene therapy Itvisma (onasemnogene abeparvovec-brve; Novartis, East Hanover, NJ).